Navigation Links
AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
Date:2/13/2009

Top Global Pharmaceutical Company Integrates Their Clinical Data System (CDS) and East(R) for Improved Clinical Data Handling and Trial Analysis

CAMBRIDGE, Mass., Feb. 13 /PRNewswire/ -- Cytel Inc. today announced that AstraZeneca International has expanded their deployment of Cytel's East(R) software, the most widely-used clinical trial design, simulation and monitoring system available. AstraZeneca's increased use of East(R) also features automated data transfer between their CDS and East's trial monitoring component. By eliminating manual data entry, AstraZeneca achieved the multiple benefits of greater clinical trial analysis efficiency and increased security of vital study data.

Cytel Vice President of Business Development, Steve Herbert, recalled the initial request: "AstraZeneca came to Cytel looking to improve data entry into East(R) from their own Clinical Data System (CDS). Our software engineers worked closely with their AstraZeneca's counterparts to help achieve far more efficient data handling within their CDS path and ensure compliance with Clinical Data Interchange Standards Consortium (CDISC) guidelines."

Maria Johansson, Business Tools Manager at AstraZeneca praised Cytel's response saying, "Cytel's customized version of East(R) for AstraZeneca is now fully integrated with our clinical data system eliminating any manual data handling and better facilitating the data analysis process. This new automation also helps us maintain the integrity of the interim data, reducing the risk of unintentional un-blinding."

Of the experience, Mrs. Johansson remarked, "The cooperation between AstraZeneca and Cytel has been very good. We're very pleased with the outcome."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

About Cytel

Cytel Inc. is a leading provider of clinical trial design services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel's East(R) system is used at hundreds of commercial sites, throughout academia and by regulators to design, simulate and monitor adaptive and group sequential clinical trials. Cytel provides trial sponsors with innovative tools, training and consultation to increase the return on investment in clinical development.


'/>"/>
SOURCE Cytel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
2. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
3. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. Melior Enters Research Collaboration with AstraZeneca
6. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
7. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
8. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
9. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
10. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
11. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), ... Chief Executive Officer, Bill Welch , will be ... 2017 at 9:00 AM EDT at the Essex House ... Welch, and Chief Scientific Officer, Mark Erlander , ... during the conference.   The presentation will be ...
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
Breaking Biology News(10 mins):